Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion’s Magsense™ technology, which provide specific targeting of cancerous cells,
In our September newsletter we announced that researchers at the University of Sydney had received an industry collaboration grant to investigate the use of our
Click play icon ▶️ to listen (transcript follows below): As a sought-after medical imaging industry thought leader, Mike Harsh sat for a recorded interview by
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding out more,
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
This video (below) captures the opening minutes of CEO Bob Proulx’s address to the 2016 NobleCon meeting, where he outlines the medical need for a
In accord with ASX requirements, Imagion Biosystems’ quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July, 2017, accompanied by
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
